Anlotinib plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: A prospective, single-arm, single-center, phase II clinical study

被引：1
|
作者：
Chen, X. [1 ]
Zhang, S. [1 ]
Li, X. [2 ]
Zhang, Y. [1 ]
Li, Y. [2 ]
Kang, H. [1 ]
Guan, H. [1 ]
She, Q. [2 ]
Ma, X. B. [1 ]
Diao, Y. [1 ]
Liu, D. [1 ]
Min, W. [1 ]
Liu, M. [1 ]
Wu, F. [1 ]
Feng, C. [1 ]
机构：
[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Oncol, Xian, Peoples R China
[2] Baoji Cent Hosp, Oncol, Baoji, Shaanxi, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.450
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
169P
引用
收藏
页码：S433 / S433
页数：1
相关论文
共 50 条
  • [31] Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland
    Andrea Favre-Bulle
    Min Huang
    Amin Haiderali
    Arjun Bhadhuri
    PharmacoEconomics - Open, 2024, 8 : 91 - 101
  • [32] The Efficacy and Safety Results of Neoadjuvant Phase II study of Anlotinib plus Sintilimab Combined with Chemotherapy in Triple-negative Breast Cancer (NeoSACT)
    Zhang, Liulu
    Yang, Mei
    Yang, Ciqiu
    Zhu, Teng
    Gao, Hong-Fei
    Wang, Kun
    CANCER RESEARCH, 2024, 84 (09)
  • [33] Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis
    Cortes, Javier
    Haiderali, Amin
    Huang, Min
    Pan, Wilbur
    Schmid, Peter
    Akers, Katherine G.
    Park, Julie E.
    Frederickson, Andrew M.
    Fasching, Peter A.
    O'Shaughnessy, Joyce
    BMC CANCER, 2023, 23 (01)
  • [34] Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis
    Javier Cortes
    Amin Haiderali
    Min Huang
    Wilbur Pan
    Peter Schmid
    Katherine G. Akers
    Julie E. Park
    Andrew M. Frederickson
    Peter A. Fasching
    Joyce O’Shaughnessy
    BMC Cancer, 23 (1)
  • [35] Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): A single-arm phase 2 trial.
    Loi, Sherene
    Francis, Prudence A.
    Zdenkowski, Nicholas
    Gebski, Val
    Fox, Stephen B.
    White, Michelle
    Kiely, Belinda Emma
    Woodward, Natasha E.
    Hui, Rina
    Redfern, Andrew David
    Calvert, Raewyn
    Rennie, Lauren
    Boyle, Frances M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] Anlotinib in patients with recurrent platinum-resistant or -refractory ovarian carcinoma: A prospective, single-arm, single-center, phase II clinical study
    Wang, H.
    Shan, B.
    Shen, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S733 - S733
  • [37] Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study
    He, Min
    Hao, Shuang
    Ma, LinXiaoxi
    Xiu, BingQiu
    Yang, BenLong
    Wang, ZeHao
    Xue, JingYan
    Chi, YaYun
    Xiong, Min
    Chen, Jiajian
    Huang, XiaoYan
    Liu, XiYu
    Wu, SongYang
    Xiao, Qin
    Huang, Yan
    Shui, RuoHong
    Cao, AYong
    Li, JunJie
    Di, GenHong
    Yang, WenTao
    Hu, Xin
    Liu, GuangYu
    Yu, KeDa
    Jiang, YiZhou
    Wang, ZhongHua
    Shao, ZhiMing
    Wu, Jiong
    ECLINICALMEDICINE, 2024, 74
  • [38] A prospective, single-arm, single-center, exploratory clinical study of anlotinib combined with irinotecan in second-line and above treatment of HER-2-negative advanced breast cancer
    Zhang, Y.
    Xu, W.
    Zhao, Y.
    Guo, X.
    Hong, T.
    Yan, Y.
    Wu, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S370 - S370
  • [39] Neoadjuvant tislelizumab plus chemotherapy among patients with advanced ovarian cancer: A prospective, single-arm, phase II study
    Zhou, Jinhua
    Liu, Wei
    Huang, Yazhen
    Ding, Hongmei
    Chen, Youguo
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S298 - S299
  • [40] A prospective, single-arm, single-center, exploratory clinical study of anlotinib combined with irinotecan in second-line and above treatment of HER-2-negative advanced breast cancer
    Zhang, Ying
    Xu, Wenhuan
    Zhao, Yutian
    Guo, Xuedan
    Hong, Tingting
    Yan, Yidan
    Wu, Xiaohong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345